IRA impact on biopharma: Latest SEC disclosures range from unknown to negative

Drugmakers are attempting to detail how they expect Medicare’s drug price “negotiations” (a term now co-opted by the biopharma industry as “price setting”) to impact their businesses as CMS begins to lay out pricing rules for a small subset of the highest spending single-source drugs and biologics reimbursed under Medicare...

Click to view original post